Hyper Corporation 30Q1: Operating Loss Narrows, Debt Ratio Improves

Consolidated Q1 2026: Revenue KRW 23.5bn, operating loss KRW 0.47bn (narrowed from KRW 4.28bn in prior year), net loss KRW 2.36bn.
Consolidated debt ratio improved to 117.46% from 250.77% at year-end 2025 (driven by rights offering and capital expansion).
Small-scale merger with subsidiary Giftletter (completed on May 1, 2026).
Ongoing acquisition and sale of 15th and 16th convertible bonds before maturity (sale of 15CB KRW 11bn, acquisition of 16CB KRW 3bn, etc.).
Change in largest shareholder from FSN to JK New Technology Investment Fund No. 12 (Feb 27, 2026).
Designated as unfaithful disclosure corporation (Apr 20, 2026) related to changes in rights offering terms.
New drug pipeline: non-narcotic analgesic MDR-652 completed Phase 1 clinical trial; Alzheimer's diagnostic kit QPLEX Alz Plus undergoing new health technology assessment.
Prior-year audit report included emphasis of matter on going concern uncertainty.